Cepheid Reaches Agreement Aimed at Increasing Adoption of TB Test in Developing World | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid announced the first agreement to buy down the price of the Xpert MTB/RIF test in order to drive adoption of the technology in resource-poor areas of the world with multi-drug-resistant tuberculosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.